SGLT2 Inhibitor–Induced Sympathoinhibition

Summary: Recent clinical trial data suggest a cardiorenal protective effect of sodium glucose cotransporter 2 (SGLT2) inhibition. We demonstrate that chemical denervation in neurogenic hypertensive Schlager (BPH/2J) mice reduced blood pressure, improved glucose homeostasis, and reduced renal SGLT2 p...

Full description

Bibliographic Details
Main Authors: Lakshini Y. Herat, PhD, Aaron L. Magno, PhD, Caroline Rudnicka, BSc (Hons), Jana Hricova, BSc, MSc, Revathy Carnagarin, MBBS, MS, MD, PhD, Natalie C. Ward, PhD, Angelique Arcambal, PhD, Marcio G. Kiuchi, MD, MSc, PhD, Geoff A. Head, PhD, Markus P. Schlaich, MD, Vance B. Matthews, PhD
Format: Article
Language:English
Published: Elsevier 2020-02-01
Series:JACC: Basic to Translational Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2452302X19303699
Description
Summary:Summary: Recent clinical trial data suggest a cardiorenal protective effect of sodium glucose cotransporter 2 (SGLT2) inhibition. We demonstrate that chemical denervation in neurogenic hypertensive Schlager (BPH/2J) mice reduced blood pressure, improved glucose homeostasis, and reduced renal SGLT2 protein expression. Inhibition of SGLT2 prevented weight gain, reduced blood pressure, significantly reduced elevations of tyrosine hydroxylase and norepinephrine, and protects against endothelial dysfunction. These findings provide evidence for significant crosstalk between activation of the sympathetic nervous system and SGLT2 regulation and possible ancillary effects on endothelial function, which may contribute to the observed cardiorenal protective effects of SGLT2 inhibition. Key Words: denervation, heart, hypertension, kidney, SGLT2, sympathetic nervous system
ISSN:2452-302X